Virus-Based therapy targets deadly brain cancers in early trial
NCT ID NCT02062827
First seen Nov 01, 2025 · Last updated May 08, 2026 · Updated 28 times
Summary
This early-stage study tests the safety of a lab-modified herpes virus (M032) that delivers an immune-boosting protein (IL-12) directly into aggressive brain tumors. The trial includes 29 adults with recurrent glioblastoma or similar cancers who have already tried standard treatments. The goal is to find the safest dose and see if the virus can help control the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT GLIOBLASTOMA MULTIFORME are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Alabama at Birmingham
Birmingham, Alabama, 35294, United States
Conditions
Explore the condition pages connected to this study.